Previous research has shown that an upregulation of the ratio of CCL2 to it receptor (CCL2/CCR2) in another hormonally-responsive cancer - prostate cancer - was associated with advancement of disease, metastasis and relapse (117). Here, CCR2 is linked to prostate cancer.